High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis
- Author
- IMAM, M. H1 ; SINAKOS, E1 ; PETZ, J1 ; KEACH, J1 ; DECOOK, A. C1 ; ENDERS, F8 ; LINDOR, K. D1 ; GOSSARD, A. A1 ; KOWDLEY, K. V2 ; LUKETIC, V. A. C3 ; EDWYN HARRISON, M4 ; MCCASHLAND, T5 ; BEFELER, A. S6 ; HARNOIS, D7 ; JORGENSEN, R1
[1] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States
[2] Center for Liver Disease, Virginia Mason Medical Center, Seattle, United States
[3] Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, United States
[4] Division of Gastroenterology and Hepatology, Mayo Clinic, Arizona, United States
[5] Department of Internal Medicine, University of Nebraska, Nebraska, United States
[6] Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, United States
[7] Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, United States
[8] Biostatistics and Health Sciences Research, Mayo Clinic, Rochester, United States - Source
Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 10, pp 1185-1192, 8 p ; ref : 30 ref
- ISSN
- 0269-2813
- Scientific domain
- Pharmacology drugs
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Acide biliaire Acide ursodéoxycholique Angiocholite sténosante Complication Dose forte Facteur risque Homme Primaire Stade précoce Pathologie de l'appareil digestif Pathologie des voies biliaires
- Keyword (en)
- Bile acid Ursodeoxycholic acid Sclerosing cholangitis Complication High dose Risk factor Human Primary Early stage Digestive diseases Biliary tract disease
- Keyword (es)
- Acido biliar Acido ursodeoxicólico Angiocolitis estenosante Complicación Dosis fuerte Factor riesgo Hombre Primario Estadio precoz Aparato digestivo patología Vía biliar patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02H Digestive system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C03 Other diseases. Semiology
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24618696
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2036.2011.04863.x 
https://dx.doi.org/10.1111/j.1365-2036.2011.04863.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1185\";s:8:\"\u0000*\u0000epage\";s:4:\"1192\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAM\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"SINAKOS, E\";i:1;s:7:\"PETZ, J\";i:2;s:8:\"KEACH, J\";i:3;s:12:\"DECOOK, A. C\";i:4;s:9:\"ENDERS, F\";i:5;s:12:\"LINDOR, K. D\";i:6;s:13:\"GOSSARD, A. A\";i:7;s:13:\"KOWDLEY, K. V\";i:8;s:16:\"LUKETIC, V. A. C\";i:9;s:17:\"EDWYN HARRISON, M\";i:10;s:13:\"MCCASHLAND, T\";i:11;s:13:\"BEFELER, A. S\";i:12;s:10:\"HARNOIS, D\";i:13;s:12:\"JORGENSEN, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1185\";s:8:\"\u0000*\u0000epage\";s:4:\"1192\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAM\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"SINAKOS, E\";i:1;s:7:\"PETZ, J\";i:2;s:8:\"KEACH, J\";i:3;s:12:\"DECOOK, A. C\";i:4;s:9:\"ENDERS, F\";i:5;s:12:\"LINDOR, K. D\";i:6;s:13:\"GOSSARD, A. A\";i:7;s:13:\"KOWDLEY, K. V\";i:8;s:16:\"LUKETIC, V. A. C\";i:9;s:17:\"EDWYN HARRISON, M\";i:10;s:13:\"MCCASHLAND, T\";i:11;s:13:\"BEFELER, A. S\";i:12;s:10:\"HARNOIS, D\";i:13;s:12:\"JORGENSEN, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1185\";s:8:\"\u0000*\u0000epage\";s:4:\"1192\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAM\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"SINAKOS, E\";i:1;s:7:\"PETZ, J\";i:2;s:8:\"KEACH, J\";i:3;s:12:\"DECOOK, A. C\";i:4;s:9:\"ENDERS, F\";i:5;s:12:\"LINDOR, K. D\";i:6;s:13:\"GOSSARD, A. A\";i:7;s:13:\"KOWDLEY, K. V\";i:8;s:16:\"LUKETIC, V. A. C\";i:9;s:17:\"EDWYN HARRISON, M\";i:10;s:13:\"MCCASHLAND, T\";i:11;s:13:\"BEFELER, A. S\";i:12;s:10:\"HARNOIS, D\";i:13;s:12:\"JORGENSEN, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1185\";s:8:\"\u0000*\u0000epage\";s:4:\"1192\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAM\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"SINAKOS, E\";i:1;s:7:\"PETZ, J\";i:2;s:8:\"KEACH, J\";i:3;s:12:\"DECOOK, A. C\";i:4;s:9:\"ENDERS, F\";i:5;s:12:\"LINDOR, K. D\";i:6;s:13:\"GOSSARD, A. A\";i:7;s:13:\"KOWDLEY, K. V\";i:8;s:16:\"LUKETIC, V. A. C\";i:9;s:17:\"EDWYN HARRISON, M\";i:10;s:13:\"MCCASHLAND, T\";i:11;s:13:\"BEFELER, A. S\";i:12;s:10:\"HARNOIS, D\";i:13;s:12:\"JORGENSEN, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2036.2011.04863.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1185\";s:8:\"\u0000*\u0000epage\";s:4:\"1192\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAM\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:10:\"SINAKOS, E\";i:1;s:7:\"PETZ, J\";i:2;s:8:\"KEACH, J\";i:3;s:12:\"DECOOK, A. C\";i:4;s:9:\"ENDERS, F\";i:5;s:12:\"LINDOR, K. D\";i:6;s:13:\"GOSSARD, A. A\";i:7;s:13:\"KOWDLEY, K. V\";i:8;s:16:\"LUKETIC, V. A. C\";i:9;s:17:\"EDWYN HARRISON, M\";i:10;s:13:\"MCCASHLAND, T\";i:11;s:13:\"BEFELER, A. S\";i:12;s:10:\"HARNOIS, D\";i:13;s:12:\"JORGENSEN, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:125:\"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
